Acquisition
Aug 2025AbbVie announced a definitive agreement to acquire bretisilocin for up to $1.2 billion, including upfront payment and milestones, and Gilgamesh planned to spin out the remaining company and programs.
SourceGilgamesh Pharmaceuticals, a Clinical stage biotechnology company…
Company research
Public company, workplace, funding, and market signals
Overview
Gilgamesh Pharmaceuticals is a New York-based clinical-stage neuroscience biotech founded in 2019 that develops novel chemical entities for psychiatric disease, with a focus on rapid-acting, durable therapies. Its current lead program is blixeprodil (GM-1020), an oral NMDA receptor antagonist for major depressive disorder; its earlier lead, bretisilocin, was acquired by AbbVie in 2025.
Primary product
Blixeprodil (GM-1020)
Founded
2019
Headquarters
New York, New York, United States
Team size
20-30
Work style
Flexible
Industry
Pharmaceutical Manufacturing
Sub-industry
Clinical-stage neuroscience biotech
Offices
New York, New York, United States
Linville, North Carolina, United States
Business model
clinical-stage drug discovery and development
pharma partnering and licensing
research collaborations
Funding
Stage
Series A
Total raised
$149.5M
Latest round
Series A · Mar 2026
Latest amount
$60M
People & investors
Leadership
Founder, CEO
Co-Founder, CSO
Chief Strategy & Development Officer
Chief Medical Officer
Chief Business Officer & Head of Research
Chief Operating Officer
EVP of Biology and Translational Medicine
Work & culture
Mission-driven, science-heavy, and compact; public messaging emphasizes experienced drug-development leadership, rapid-acting and durable psychiatric therapies, and partnership-oriented execution.
Work style
Flexible
Compensation
No public salary bands were found. Hiring posts indicate senior US-based, fully remote roles; one CMC - Drug Substance posting asked for a PhD and 5-10+ years of experience.
Product & market
Pricing
Not publicly disclosed; appears to be a B2B biopharma partnering/licensing model.
Differentiators
- —Develops novel chemical entities rather than incremental reformulations
- —Focuses on rapid-acting, durable psychiatric therapies
- —Lead program blixeprodil is an oral NMDA receptor antagonist
- —Pipeline is designed around precedented mechanisms with an emphasis on safety, efficacy, and patient access
Competitors
Xylo Bio
Scale & contact
Estimated revenue
approximately $6M (public estimates range $1M-$10M)
Estimated monthly visits
12.9K
Traffic estimate as of Jul 2026
Signals & risks
Other
Oct 2025AbbVie completed its acquisition of Gilgamesh Pharmaceuticals' bretisilocin, leaving the remaining programs and employees in the spun-out Gilgamesh Pharma entity.
SourceLatest news
PRNewswire · Mar 2026
Announced a $60M Series A led by Satori Neuro; described the spinout company and its lead program blixeprodil.
PRNewswire · Jan 2026
Reported positive Phase 2a data for the oral NMDA receptor antagonist blixeprodil, including durable antidepressant effects.
AbbVie · Oct 2025
AbbVie completed its acquisition of bretisilocin, expanding its psychiatry pipeline.
AbbVie · Aug 2025
Definitive agreement for AbbVie to acquire bretisilocin for up to $1.2B and spin out the remaining Gilgamesh business.
PRNewswire · May 2025
Reported positive Phase 2a data for GM-2505/bretisilocin, including high remission rates and durable efficacy.
Jobs and careers at Gilgamesh Pharmaceuticals
0 jobs at Gilgamesh Pharmaceuticals
No open positions
Check back later for new openings